Emerging evidence indicates an intricate interaction between GMB-derived metabolites, metabolic syndrome, and cellular dysregulation, such as mitochondrial and ELN dysfunction, in AD pathogenesis (Table 1). This evidence concerns the gene ELN and Alzheimer disease.